Aberrant methylation limits antitumoral inflammation in lung adenocarcinoma by restricting RIPK3 expression
Science Advances · 2026
DOI: 10.1126/sciadv.adz9227 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Deepti Agrawal und 19 weiteren Autor:innen. Beteiligte Einrichtung: Medical Department III, School of Medicine, Technical University of Munich, Munich, Germany. Hauptthemen laut MEDLINE: Receptor-Interacting Protein Serine-Threonine Kinases, Adenocarcinoma of Lung, DNA Methylation, Gene Expression Regulation, Neoplastic. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: ASCRS Research Foundation, Wellcome, H2020 European Research Council.
Abstract (Originalsprache)
Evasion of programmed cell death is a critical hallmark of cancer. However, the contribution of inflammatory forms of cell death in lung carcinogenesis and their effects on the composition of the tumor-immune microenvironment remain unclear. Our multi-omics analyses of samples from patients with primary lung adenocarcinoma revealed that necrosome signaling is repressed because of reduced expression of receptor-interacting protein kinase 3 ( RIPK3 ). Distinct methylation signatures, both in the RIPK3 promoter and nonpromoter regions, correlated with lower transcription levels of RIPK3 . This resulted in limited expression of inflammatory genes, advanced histologic features, reduced immune cell invasion, and decreased patient survival. Mechanistically, we confirmed the tumor-suppressive role of necrosome signaling through the genetic deletion of Ripk3 in two independent, clinically relevant mouse models of lung adenocarcinoma. Functionally, RIPK3 shaped a diverse immune environment by promoting the invasion of innate and adaptive immune cells in patient samples and experimental mice. Thus, RIPK3-mediated inflammatory signaling enhances a diverse immune microenvironment and hinders progression in lung adenocarcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Department III, School of Medicine, Technical University of Munich, Munich, Germany.
- Division of Oncology, Medical University of Graz, Graz, Austria.
- Department of Medicine III, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
- German Cancer Consortium, Partner site Munich, Munich, Germany.
- German Cancer Research Center, Heidelberg, Germany.
- Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
ORCID-Profile: Deepti Agrawal, Katarina Cisarova, Sebastian Vosberg, Fabian Allmendinger, Nadia Dandachi, Vanessa Jäger, Martina Anton, Eva C Keller, Tobias Stoeger, Katja Steiger, Nicholas McGranahan, Michael A Dengler, Adam Wahida, Philipp J Jost
Förderung
- ASCRS Research Foundation
- Wellcome
- H2020 European Research Council
- Deutsche Krebshilfe
- Deutschen Konsortium für Translationale Krebsforschung
- German Ministry for Education and Research
- Deutsches Zentrum für Lungenforschung
- German Research Society
Zitieren
APA
Agrawal, D., Cisarova, K., Vosberg, S., Allmendinger, F., Munkhbaatar, E., Dandachi, N., Fernandez Hernandez, F. J., Tonietto, M., Jäger, V., Anton, M., Keller, E. C., Jesinghaus, M., Meinhardt, A. L., Haefner, V., Stoeger, T., Steiger, K., McGranahan, N., Dengler, M. A., Wahida, A., & Jost, P. J. (2026). Aberrant methylation limits antitumoral inflammation in lung adenocarcinoma by restricting RIPK3 expression. Science Advances. https://doi.org/10.1126/sciadv.adz9227
Vancouver
Agrawal D, Cisarova K, Vosberg S, Allmendinger F, Munkhbaatar E, Dandachi N, et al. Aberrant methylation limits antitumoral inflammation in lung adenocarcinoma by restricting RIPK3 expression. Science Advances. 2026. doi:10.1126/sciadv.adz9227
BibTeX
@article{Agrawal2026,
author = {Agrawal, Deepti and Cisarova, Katarina and Vosberg, Sebastian and Allmendinger, Fabian and Munkhbaatar, Enkhtsetseg and Dandachi, Nadia and Fernandez Hernandez, Francisco Jose and Tonietto, Marta and Jäger, Vanessa and Anton, Martina and Keller, Eva C and Jesinghaus, Moritz and Meinhardt, Anna-Lena and Haefner, Verena and Stoeger, Tobias and Steiger, Katja and McGranahan, Nicholas and Dengler, Michael A and Wahida, Adam and Jost, Philipp J},
title = {Aberrant methylation limits antitumoral inflammation in lung adenocarcinoma by restricting RIPK3 expression},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.adz9227}
}
EUVIMED